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AbstrACt
Objectives Antidepressant prescribing almost doubled 
in the Netherlands between 1996 and 2012, which could 
be accounted for by longer continuation after the first 
prescription. This might be problematic given a growing 
concern of large-scale antidepressant dependence. We 
aimed to assess the extent and determinants of chronic 
antidepressant prescribing among patient aged 18 years 
and older. We hypothesise a relatively large prevalence of 
chronic (>2 years) prescription.
Design A longitudinal observational study based on 
routinely registered prescription data from general 
practice.
setting 189 general practices in the Netherlands.
Participants 326 025 patients with valid prescription data 
for all 5 years of the study.
Outcome measures Primary outcome measure: 
the number of patients (N) receiving at least four 
antidepressant prescriptions in 2011, as well as during 
each of the four subsequent years. Secondary outcome 
measure: the above, but specified for selective serotonin 
reuptake inhibitors and for tricyclic antidepressants.
results Antidepressants were prescribed to almost 7% of 
our 326 025 participants each year. They were prescribed 
for depression (38%), anxiety (17%), other psychological 
disorders (20%) and non-psychological indications (25%). 
Antidepressants were prescribed in all 5 years to the 
42% of the population who had at least four prescriptions 
dispensed in 2011. Chronic prescribing was higher among 
women than men, for those aged 45–64 years than for 
those aged >65 years and for those treated for depression 
or anxiety than for non-psychological indications (eg, 
neuropathic pain). Chronic prescribing also varied 
markedly among general practices.
Conclusion Chronic antidepressant use is common 
for depression and for anxiety and non-psychological 
diagnoses. Once antidepressants have been prescribed, 
general practitioners and other prescribers should be 
aware of the risks associated with long-term use and 
should provide annual monitoring of the continued need 
for therapy.
IntrODuCtIOn 
Antidepressants are recommended for the 
treatment of both major depression and 
anxiety disorders in most clinical guidelines. 
Based on evidence that they are more effi-
cacious than placebo in adults with major 
depressive disorder,1 antidepressants were 
used by more than 12% of the adult US 
population in 2013, with the prevalence in 
women being approximately double than in 
men, and increasing with age.2 However, anti-
depressants are also prescribed off-label for 
disorders other than depression, most often 
in nursing homes and for older populations, 
with evidence supporting off-label use avail-
able in Dutch, UK, Swedish, Canadian and 
US populations.3–7 In the Netherlands, selec-
tive serotonin reuptake inhibitors (SSRIs) 
have typically been prescribed off-label for 
other psychological problems, while tricyclic 
antidepressants (TCAs) have tended to be 
preferred for pain disorders.3 
Dutch guidelines for the treatment of 
depression in general practice initially recom-
mend watchful waiting and non-medical 
therapy, except for comparably rare presen-
tations with suicidal ideation or psychosis. If 
symptoms persist, antidepressant medication 
can be considered if a depressive disorder 
is present, but not merely for the presence 
of depressive symptoms.8 According to the 
Dutch College of General Practitioners, 
psychopharmacological agents should not 
be used to treat anxiety symptoms, but 
they are considered to have efficacy for 
anxiety disorders.9 Despite this cautious 
approach, the prevalence of antidepressant 
strengths and limitations of this study
 ► Large database, largely representative for Dutch 
population.
 ► Routinely collected prescription data, reliable be-
cause needed for delivery by pharmacist.
 ► Morbidity data, needed for prescription indication, 
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prescribing almost doubled between 1996 and 2012 in 
the Netherlands.10
In the 1990s, there was an increase in the prevalence 
and incidence of SSRI use, with more patients starting 
SSRIs and receiving antidepressant therapy for longer 
durations.11–16 An explanation for this increase in antide-
pressant prescribing might, therefore, be longer contin-
uation after initial treatment. For example, Mars et al14 
reported that the incidence of antidepressant prescrip-
tions was stable between 1995 and 2011, but that the 
prevalence more than doubled in the same period. In 
the Netherlands, Noordam et al10 showed the same trends 
between 1996 and 2012. Given that equal numbers start 
therapy each year, but the total number of users increases, 
the increase in prevalence might reflect longer continua-
tion of therapy.
Long-term antidepressant use has been reported in 
several studies that have used primary care databases. 
In a recent Dutch study, antidepressants were used for 
long term (>15 months) by 30% and 44% in the periods 
1995–2005 and 2005–2015, respectively.17 In a study of 
a primary care database from Scotland, 40% of patients 
received SSRIs for longer than 180 days, and it was shown 
that practice variation accounted for most of the differ-
ences in prescribing durations.18 In UK general practice, 
it has been reported that the mean durations of antide-
pressant treatment were 4.8 years for depression, 7.4 years 
for anxiety and 5 years for pain.19 Read et al also reported 
that 52% of a New Zealand sample continued antidepres-
sant treatment for 3 or more years, with this proportion 
increasing with age,20 while Ambresin et al  reported that 
therapy was continued for more than 2 years in 47% of 
antidepressant users. However, Sihvo et al12 reported that 
only 14% of antidepressant users in Finland continued 
therapy for more than 2 years. The results of an Austra-
lian study were consistent with this latter finding, showing 
that 50% and 61% of new antidepressant users had 
discontinued therapy within 6 and 12 months, respec-
tively, and that only 20% had continued therapy at 3 years. 
Receiving psychological or psychiatric care was associated 
with longer antidepressant use, while the presence of 
either cancer or multiple morbidities was associated with 
an increased likelihood of shorter treatment duration.21
Little is known about the factors associated with long-
term antidepressant use. Moreover, although current 
Dutch guidelines recommend stopping treatment 
6 months after remission,9 they are not explicit about 
how to stop or about when long-term continuation is 
appropriate. Regular monitoring and medication reviews 
are also recommended when prescribing continues in 
the long term. Overall, the current real-world situation 
raises many questions about the appropriateness of the 
current guidelines for clinical practice. Therefore, we 
aimed to assess the extent of chronic antidepressant 
prescribing and to evaluate the determinants of that 
chronic prescribing. Our main research questions were 
what proportion of patients were prescribed antide-
pressants continuously during a 5 year period and what 
predicted long-term prescribing? We also wanted to 
answer four specific sub-questions1: What proportions of 
patients continue therapy for more than 2, 3 and 4 years?2 
Are there differences in long-term prescribing by sex and 
age?3 Are there differences in long-term prescribing by 
the indication for antidepressant prescribing? and4 Are 
there differences in long-term prescribing between SSRIs 
and TCAs?
MethOD
study design and participants
This was a cross-sectional observational study based on 
the data obtained in the NIVEL Primary Care Database 
(NPCD). Participants were all patients aged 18 years and 
older, registered in Dutch general practices participating 
in the NPCD.
nIVeL database
Data were obtained from the NPCD. This database 
contains routinely collected data on symptoms, diagnoses, 
medications and laboratory results related to the consul-
tations for patients from 367 to 519 general practices (the 
number of participating practices each year varied) in the 
Netherlands. All non-institutionalised inhabitants of the 
Netherlands are registered at a general practice, and the 
general practices and patient populations in the NPCD 
have proven representativeness for wider Dutch society, 
although group practices are somewhat over-represented. 
For this study, we used data for adult patients aged 18 
years and older, covering the period 2011–2015.
Patient and public involvement
Patients and public were not involved in design or 
conduct of the study.
Data
Prescriptions
Each medication prescription, including repeat prescrip-
tions, were recorded by date and code based on the 
Anatomical Therapeutic Chemical Classification System 
(ie, ATC codes). The following codes for antidepres-
sants were included: N06AA (TCA), N06AB (SSRI), 
N06AF (non-selective monoamine oxidase inhibitors 
(MAOI)), N06AG (type A MAOI) and N06AX (other 
antidepressants).
Diagnosis
Symptoms and diagnoses related to a given prescription 
were classified according to the International Classifica-
tion of Primary Care,22 using the P.xxxx codes for psycho-
logical symptoms and disorders. Codes P03 (depressive 
symptom) and P76 (depressive disorder) were taken to 
mean ‘depression’, while codes P01 (feeling nervous) 
and P74 (anxiety disorder) were taken to mean ‘anxiety’. 
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Prevalence of antidepressant prescription
For each year, we calculated the number of patients (N) 
prescribed an antidepressant, SSRI or TCA and whether 
the prescription was linked to a record of depression, 
anxiety or other disorder (non-psychological/somatic). 
We recorded the number of patients with a prescription 
per 1000 patient-years, linked to age and gender, within 
a certain year. These data allow for extrapolation to the 
Dutch population based on a yearly weighted population 
at risk in the NPCD, which varied annually from 1 087 395 
to 1 641 806 patient-years.
Long-term use
To calculate the numbers of patients using prescriptions 
for several years, the data for different years were merged 
to give the number of patients with a recorded antide-
pressant prescription and diagnosis of depression in each 
of the study years (ie, 2011, 2012, 2013, 2014 and 2015). 
Merging data for the 5 subsequent years resulted in a loss 
of cases, because the NIVEL database did not include all 
practices or patients in some years.
statistical analysis
We use multilevel logistic regression with patients clus-
tered by general practice. The models were then anal-
ysed in MLwiN V.2.30,23 using the options ‘PQL’ and 
‘second order’ (‘first order’ was used if the model failed 
to converge), and ‘constrained level one variance’.
Outcome measures
The main outcome measure was the number of patients 
(N) receiving at least four antidepressant prescriptions in 
2011, as well as during each of the 4 subsequent years. 
We assumed that receiving four or more prescriptions 
in 1 year was consistent with chronic use, based on the 
common Dutch practice to prescribe antidepressants on 
repeat prescriptions for 3-month periods.
Independent variables
At level 1, we controlled for variation at the practice level. 
At level 2, the patient level, we considered age in 2011, 
sex and diagnosis associated with the prescription (ie, 
depression, anxiety or somatic problem).
resuLts
The results about long-term antidepressants use are based 
on data for 326 025 patients (older than 18 years) from 
189 practices with valid prescription data for all 5 years 
of the study. In 2011, antidepressants were prescribed 
to ±71/1000 registered patients aged ≥18 years. About 
two-thirds of the prescriptions were for women and about 
one-third were for men. 30% of antidepressants were 
prescribed to those aged 18–44 years, 45% to 45–64 years 
old and 25% to those above 65 years. The distribution of 
the population at risk in 2011 was 43:37:20.
Of the antidepressants prescribed, SSRIs and TCAs 
accounted for 52% and 28%, respectively. Overall, 38% 
were prescribed for depression, 17% for anxiety, 20% 
for other psychological diagnoses and 25% for somatic 
indications. SSRIs were more frequently prescribed 
for depression (47%) and anxiety (23%), while TCAs 
tended to be prescribed frequently for somatic disor-
ders (44%) or other psychological disorders (21%). The 
main somatic indications for TCAs were generalised 
pain (1.7%), lumbago (2.5%), low back pain with radi-
ation (2.5%), headache (2.7%), tension headache (2%), 
neuropathy (4.8%), sleeping problems (4.1%) and type 2 
diabetes mellitus (1.5%).
The data for the proportions of patients who continued 
to be prescribed antidepressants in each year after 2011 
are summarised in figure 1 and table 1.
Of those who received at least four prescriptions in 
2011, we found that 65% were still receiving at least four 
prescriptions per year at 2 years and that 58% were still 
receiving them at 3 years. However, only 42% of patients 
received at least four prescriptions of antidepressants 
through each year from 2011 to 2015; by SSRI and TCA 
use, this was 38% and 35%, respectively (figure 1).
When we lower the threshold for chronic prescribing to 
at least one prescription a year, 65% of patients receiving 
an AD prescription in 2011 kept receiving yearly at least 
one prescription each year to 2015.
The odds for receiving antidepressants over 5 consecu-
tive years based on patients’ characteristics are shown in 
table 1.
Specifically, the odds were higher for women than for 
men, for patients aged 45–65 years and for a diagnosis 
of anxiety or depression. However, there was substantial 
practice variation, meaning that the proportions were 
even larger in some practices but much smaller in others. 
Online supplementary tables 1 and 2 in the appendix show 
similar patterns for SSRIs and TCAs analysed separately, 
though with some exceptions. A diagnosis of anxiety, for 
example, did not affect long-term SSRI prescribing. Also, 
sex and older age affected long-term TCA prescribing, 
but indication did not.
Figure 1 Number of AD-users in 2011, who used AD 
chronically (≥4 prescription/year) in the subsequent 
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DIsCussIOn
Antidepressants were prescribed to almost 7% of the 
general practice population, aged 18 years and older, in 
this study. The main indication was for depression (38%), 
but anxiety (17%), other psychological disorders (20%) 
and non-psychological indications, mostly pain related 
(25%), were frequent. Interestingly, nearly half of the 
population (42%) received antidepressants throughout 
all 5 years of the study. The odds of long-term use were 
higher for women than for men, for those aged 45–64 
years than for those aged ≥65 years and for those with 
psychological indications than for those with non-psy-
chological indications. However, long-term prescribing 
habits varied markedly among practices.
Consistent with our results, Huijbregts et al17 reported 
that about 44% of antidepressant use was long term 
(defined as >15 months) based on one region in the 
Netherlands. In our larger nationwide population, with 
a much stricter definition of long-term use as 5 years of 
continuous receipt of four antidepressant prescriptions a 
year, 42% used antidepressants chronically. We also found 
the same risk factors for long-term use, with female sex, 
older age and having a diagnosis of anxiety or depression 
being most important. However, in contrast with their 
data, we found that the group aged 45–64 years was at 
higher risk than the group aged ≥65 years.
Antidepressant medication use is a prominent topic 
of discussion in society. Opponents of their wide-
spread use, such as Gøtzsche24 and Greenberg,25 point 
to the lack of efficacy and the possible harms of long-
term use. Risk of falls and fractures, upper gastrointes-
tinal bleed and epilepsy/seizures is increased among 
adult (20–64 years) AD users.26 27 A higher risk for 
falls, attempted suicides, stroke, fracture and epilepsy 
is reported for older people, using AD.28 By contrast, 
proponents, such as Allan H Young and John Crace, 
cited in Gøtzsche et al,29 consider psychiatric drugs to be 
as beneficial as other medical treatments and argue that 
concerns about long-term use are overinflated. So, just 
how harmful is antidepressant use in the long term? We 
know that antidepressant use is now on a large scale, partly 
for depression and anxiety, but also for other psycholog-
ical and non-psychological indications. This is important 
to understand because antidepressants have only demon-
strated slight effectiveness for the treatment of depression 
and anxiety,30 and have unknown efficacy for those other 
disorders. Although some patients will benefit from long-
term use,31 at best, such use may be unhelpful to many 
patients. Indeed, there is no conclusive evidence about 
the safety of antidepressants over years, and Andrews et 
al even claim that such use will generally do more harm 
than good by disrupting key adaptive processes regulated 
by serotonin.32 Harm may also be expected among older 
antidepressant users who are at risk of polypharmacy; 
antidepressant use, for example, has an important nega-
tive impact on the Drug Burden Index, an indicator of the 
cholinergic and sedative stress imposed by medication.33
At first glance, general practitioners (GPs) might view 
antidepressant treatment as a good initial therapy that is 
in the patient’s interest. Despite the potential risks, and 
perhaps because of the lack of clear evidence of harm, 
or reports of continuation problems, the option of long-
term use also remains acceptable.34 This is compounded 
by the fact that, when patients have benefited from relief 
of depressive symptoms, they often become reluctant 
to stop therapy for fear of becoming depressed again.35 
Therefore, large groups of patients with single episodes 
of low severity depression, who probably received effec-
tive antidepressant therapy in the beginning, progress to 
long-term use with less clearly defined benefits.
Table 1 Odds for receiving an antidepressant for each year between 2011 and 2015 after receiving the first prescription in 
2011
Variable Coefficient SE P value OR 95% CI
Sex (ref=male)
  Female 0.1400 0.0409 P<0.001 1.15 1.06 to 1.25
Age (ref=65+  years)
  19–44 −0.1161 0.0541 0.0320 0.89 0.80 to 0.99
  45–64 0.2320 0.0476 P<0.001 1.26 1.15 to 1.38
Disorder
  Anxiety (ref=no anxiety) 0.3196 0.0558 P<0.001 1.38 1.23 to 1.54
  Depression 
(ref=no depression)
0.3224 0.0488 P<0.001 1.38 1.25 to 1.52
  Somatic disorder 
(ref=no somatic disorder)
0.0153 0.0565 0.7864 1.02 0.91 to 1.13
Practice variance 6.763 0.8653
ICC 0.67
Constant −4.2012 0.2276
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A way to prevent unnecessary long-term antidepressant 
use might be to institute annual medication reviews. This 
issue is especially pertinent given that proactive medica-
tion reviews have been reported to become increasingly 
sparse the longer antidepressants have been prescribed, 
especially when not for an overt mental health reason.36
The large practice variation that we found suggests long-
term AD prescribing to be a practice policy, as has been 
reported in the case of antibiotics prescribing,37 where 
patient characteristics could not explain the variation at 
practice level as well.38 Medication reviews may reflect 
such a policy, possibly by routine consultations between 
GP and pharmacist. As proven in other studies, medica-
tion reviews may be routine in some practices, leading 
to reduced long-term antidepressant use, but may be 
non-existent in other practices, with opposing results.39 
New initiatives, such as the introduction of tapering 
strips40 or the continuous monitoring of patients who 
discontinue antidepressants, could offer new insights and 
help develop recommendations for GPs to help patients 
stop treatment when it is no longer needed. Developing 
a consensus on how to discontinue antidepressants in 
general practice could reduce practice variation and 
decrease the proportions of patients who continue to take 
antidepressants beyond the required period for acute 
treatment and stabilisation.
Limitations
Although prescription data were available of 1–2 million 
patients, substantial numbers were lost by merging 
prescription and morbidity data (providing us with the 
indication) and by merging the data over several years 
(eg, some practices were not part of the NPCD for the 
full period and some patients were not registered for the 
full period). Therefore, the final analyses were conducted 
on 326 025 cases from 189 practices. This final sample 
included more patients aged >45 years and fewer men 
compared with the original database, so may have not 
been truly representative of the Dutch population. Our 
definition of chronic prescribing (at least four prescrip-
tions in all years) is arbitrary. However, when we increase 
the threshold to, for example, five prescriptions a year, 
chronic users having a repeat prescription each 3 months 
would not be included. When we decrease the threshold 
to one prescription in each of 5 years, the number of 
‘chronic users’ increases to 65%. Morbidity data were also 
highly dependent on the coding registered by the GP. It is 
well known that GP variations in diagnosis are large and 
that sensitivity can be suboptimal.41 However, the anti-
depressant prescribing data were not dependent on the 
morbidity coding, which is a major strength.
Conclusions
Chronic antidepressant use was common in this cohort, 
with 42% of patients prescribed antidepressants in 2011 
continuing to use them at 5 years. Although the initial 
prescribing of antidepressants might have become stable, 
patients continue to take their prescriptions for many 
years, though with considerable variation in this trend 
between practices. It was noteworthy that depression was 
not the main indication for antidepressant prescription, 
with a quarter of prescriptions being for non-psycholog-
ical indications and a fifth being for anxiety. Therefore, 
we conclude that the high levels of antidepressant use can 
only partly be attributed to depression, with the main issue 
appearing to be an increase in chronic usage after initial 
prescribing. GPs and other prescribers should be aware 
of the risks of long-term antidepressant use and ensure 
annual monitoring to reduce unnecessary prescribing.
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